The systemic and cardiorenal benefits of GLP-1 RA support their use in cardio-oncology models, due to their anti-obesity and anti-inflammatory effects, driven by the activation of cAMP, PI3K/Akt and AMPK pathways and systemic increases in adiponectin and ET-1 levels. The gene discussed is AKT1; the disease is obesity disorder.